Skip to main content

News

| Article
Association for Molecular Pathology issues helpful Recommendations to Labs for Responsible PGx Test Offerings

The American AMP is responding with a position paper to the FDA-evoked discussions around PGx with clear recommendations on gene drug targets, laboratory and delivery of information for the POC.

Read more:

Article on genomeweb

Association for Molecular Pathology Position Statement

Read more about Association for Molecular Pathology issues helpful Recommendations to Labs for Responsible PGx Test Offerings >
| Article
Is pharmacogenetic testing slowly becoming mainstream?

The FDA's attention and UHC coverage indicate that PGx testing is finally coming to the standard care - in the US ...

Read free article on genomeweb.

Read more about Is pharmacogenetic testing slowly becoming mainstream? >
| Article
Article on "genetic information management systems" for pharmacogenomics in Trillium Diagnostik 2019; 17(1):16

by Daniela Steinberger
Genetisch bedingte Varianten von Proteinen des Medikamentenstoffwechsels können zu unerwünschten oder unzureichenden Arzneimittelwirkungen (UAW) führen.

Read more about Article on "genetic information management systems" for pharmacogenomics in Trillium Diagnostik 2019; 17(1):16 >
| Article
Digitale Gesundheitskompetenz: Datensouveränität als Ziel

Patient Empowerment/Förderung von E-Health Literacy/Shared Decision Making/digitale Patientenakten und Datenhoheit
Hier geht es zum vollständigen Artikel von Heike E. Krüger-Brand im Deutschen Ärzteblatt (Dtsch Arztebl 2019; 116(10): A-468 / B-382 / C-378).

Read more about Digitale Gesundheitskompetenz: Datensouveränität als Ziel >
| Article
bio.logis supports DELAB-Fachtagung with a talk on digital solutions to implement pharmacogenomics into clinical practise

Our CEO Prof. Daniela Steinberger will speak about the still to overcome challenges of implementing pharmacogenomics expertise in a clinical setting. She will show and and is happy to discuss the use of innovative digital solutions for genetic labs and hospitals to support the way towards personalised medicine and a better treatment of patients.

The talk will be held at the DELAB, Mainz, March 9th, 11:30 am.

For more information please contact us: info@biologis.com.

 

Read more about bio.logis supports DELAB-Fachtagung with a talk on digital solutions to implement pharmacogenomics into clinical practise >
| Article
European Clinics Evaluating New Card System for Making PGx Data Available to Patients

A recent article at GenomeWeb describes the joint efforts of bio.logis, the Medical University Vienna and the Robert-Bosch-Krankenhaus in Stuttgart, Germany to make pharmacogenetic analysis results available to patients through a unique drug safety card system.

Read more about European Clinics Evaluating New Card System for Making PGx Data Available to Patients >
| Press release
bio.logis Genetic Information Management GmbH bound for growth – Moving to new business premises

The company bio.logis GIM GmbH has moved into a new and larger facilities on Olof-Palme-Strasse 15 in Frankfurt am Main on 01.08.2018 - only a few minutes away from the previous location on Campus Riedberg. With its new business premises, the international company founded in 2013 has created the conditions for the planned growth in the coming years.

Read more about bio.logis Genetic Information Management GmbH bound for growth – Moving to new business premises >
| Press release
Determine the right dose using genetic information — bio.logis collaborates with KNMP, the Royal Dutch Pharmacists Association

Based on the KNMP’s (Royal Dutch Pharmacists Association) latest pharmacogenetics insights, the G-Standaard drug database provides dosage recommendations for active ingredients depending on various genotypes. This enables Dutch physicians and patients to always access the most relevant information on the kind and dosage of drugs that will work best in each individual case. This service is now also available to users of the bio.logis Genetic Information Management Suite (GIMS): Laboratories and hospitals can incorporate this information directly in their pharmacogenetics reports. The partners have already signed a license agreement, allowing GIMS to directly retrieve select data from G-Standaard dosage recommendations — regardless of the country where GIMS is being used.

Read more about Determine the right dose using genetic information — bio.logis collaborates with KNMP, the Royal Dutch Pharmacists Association >
| Article
Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects

Sehr viel mehr Menschen sterben an unerwünschten Wirkungen von Medikamenten als im Straßenverkehr. Mit der Zahl der Arzneien, die jemand einnimmt, steigt das Risiko dramatisch. Was aber, wenn selbst die Ärzte nicht weiterwissen?

Read more about Austrian Article by Franziska Dzugan in "Profil" about adverse drug effects >
| Article
Article on "Personalized Medicine" in Plattform Life Science

Seit jeher versuchen Mediziner, ihren Patienten die bestmögliche Behandlung zukommen zu lassen. Doch ist der Mensch ein kompliziertes Wesen, will sagen, jeder Mensch reagiert anders auf die ihm verschriebene Dosis an Medikamenten oder Therapien. Ganz ähnlich verhält es sich mit den Krankheiten. Ursache, Verlauf oder Härtegrad hängen von einer Vielzahl von Faktoren ab. Dies bezieht sich nicht nur auf die genetische Ausstattung der Betroffenen, ihr Alter oder ihr Geschlecht. Auch externe Umwelteinflüsse und individuelle Lebensstile haben einen Einfluss. Die Folgen dieser Umstände sind maßgeblich, denn viele konventionell hergestellte Wirkstoffe erzielen längst nicht (mehr) die erhoffte Wirkung oder bringen nicht beabsichtigte Nebenwirkungen.

Read more about Article on "Personalized Medicine" in Plattform Life Science >